My interview with Vitaccess Founder & CEO Dr Mark Larkin

October 15th 2019

Vitaccess have been based here at Oxford Centre for Innovation (OCFI) for nearly two years and, during that time, have seen steep growth. Read on and meet Vitaccess’ CEO and founder, Dr Mark Larkin.

What is Vitaccess?

We're a digital healthcare research company that uses smartphone apps to collect data directly from patients about how their condition and treatment impacts their everyday lives. The data we collect is extremely valuable and is used in a range of clinical trials and for the approval of medication.

We collect data for the following:

  • Melanoma
  • Beta-thalassemia
  • Charcot-Marie-Tooth diseases
  • Myasthenia gravis
  • Cystic fibrosis
  • Migraine

 How’s the company going?

We opened the Oxford office in March 2017 and since then it’s been going extremely well! We have seen a steep growth curve, which has allowed us to expand our team, and Vitaccess is now in several countries around the world. One of the reasons behind our success is that digital health overall is growing fast, but the way we work, which is very rigorous and scientific, means our data and our studies are used in peer-reviewed journals. We also work in a very patient-centric way and we have partnered up with patient advocacy groups in various countries where we launch our studies.

It’s been an amazing journey and it’s great to be able to have had the opportunity to build something like our digital health app. We have worked ever so hard to get this far and my team have been outstanding. One of the things that drives us here at Vitaccess, apart from making a difference through the data we collect, is the fact that we can recruit 800 patients in a week from all over the world because our product is easy to find and use.

Why did you start Vitaccess?

My background is in health economics and consulting, where we worked with clients who were interested in generating data, and I advised in many areas, one of which was strategy. However, historically, gathering this type of data was typically done by people with clipboards in supermarket car parks asking the public questions. That's hugely inefficient and expensive and clearly there were better ways of doing it. So, I thought there's an opportunity for doing this type of work using smartphones, as most people nowadays have one, and click, Vitaccess was born!

What challenges did you face early on?

One of the key hurdles we experienced, and it’s the same in most start-ups, is recruitment! I remember distinctly when I tried hiring Coralie, who is now our senior marketing and communications manager, that at the time it was a challenge as we didn’t have a 10-year track record to impress her with. However, as a start-up you do attract a certain type of person who has the excitement and enthusiasm for a challenge, which does help.  As you develop as a business this hurdle reduces as you have the results and a track record to start impressing people and providing them with confidence.

The second hurdle we faced was commercial, where you must convince clients that what you're suggesting to them is viable and a good idea, as once again you haven't got a track record. However, we managed to get around this with the help of networks we built over the years.

What is the benefit to the user?

We think about this as the “What's in it for me?” factor.  Let’s say you are a melanoma patient, why would you be interested in doing a study with us? There are a few different reasons: one is that we can build into study apps the tools to help you manage your condition. So, for instance, we have a tool that we call the “Knowledge” feature, which contains clinically validated information about different treatments, how melanoma progresses, and how it impacts people. This is not Google information, this is clinically validated information at your fingertips.

A second feature we provide allows users to contact others who have similar profiles, such as condition, location, age, or stage of their condition. We call it the “Community” feature and it allows users to communicate and even meet up for a coffee.

In addition, users can track symptoms via the app, so when they go and see their GP and the doctor asks how they have been, patients can simply open the app to access that information in a simple, straightforward format.

How has OCFI helped?

When we set up the company we had to decide where we would have our headquarters. We took this very seriously as it had to be in the right location, amongst similar-minded people and with good transport connections.  We came across OCFI and it ticked all the boxes straight away. We moved into what is now the Pod (co-working area) before shortly moving into an office under the centre’s flexible licencing agreements. The support we have received from OCFI, along with the flexible agreements, has played a key role in the growth we have seen in the past two years.

What drives you?

I have to say this is the most fun I have ever had in my career! Seriously, it's really satisfying to be able to work with people who think the same! It’s truly amazing to run a company like Vitaccess, knowing that what you and your team are doing daily is making a difference in patients’ lives and for the development of medication for future generations.

Another driving factor of mine is being able to help the causes we work with. Due to the growth we have seen we are now in a position where we have started donating money to causes. That again has a direct impact on patients. I am happy to say that in July this year Vitaccess donated £10,000 to Melanoma UK towards a body mole mapper for the Royal Liverpool and Broadgreen University Hospitals NHS Trust.

For more information about Vitaccess please visit -

Photo credit to KT Photography

June 29th 2021

Five minutes with David Llewellyn from DJS Antibodies

A dynamic new biotech started by Dr David Llewellyn and Dr Joe Illingworth, DJS Antibodies is pioneering the development of novel therapeutics to treat the world’s most critical inflammatory diseases, a class of disease that accounts for more than 50% of deaths worldwide.

June 4th 2021

Five minutes with Peter Hamley from Samsara Therapeutics

We spoke to Peter Hamley, Chief Scientific Officer of amazing biotech start-up Samsara Therapeutics, who have just moved into the new life science labs at our Wood Centre for Innovation.

May 5th 2021

Five minutes with Adam Forsyth, CTO of TZ

We spoke to Adam Forsyth CTO of TZ, an Australian start-up at the forefront of electronic locking device development and one of our newer residents at the Oxford Centre for Innovation.